Citius Oncology, Inc. CTOR Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -119.9%-72.5pp | -47.4%+7.0pp | -54.4%+53.1pp | -107.5%-13.9pp | -93.6%-21.5pp | |
| Liquidity | ||||||
| Current ratio | 0.5×-0.3× | 0.8×+0.3× | 0.6×+0.2× | 0.3×0.0× | 0.4×0.0× | |
| Per Share | ||||||
| Book value per share | $0.35-47.2% | $0.67+9.1% | $0.61+35.2% | $0.45-9.1% | $0.50-13.7% | |
| Valuation | ||||||
| Market capitalization | $60.45M-74.7% | $84.8M-50.0% | $169.53M-10.9% | $190.33M+186% | $66.54M-19.1% | |
| Price / book | 1.8×-5.9× | 1.5×-2.3× | 3.8×-2.1× | 5.9×+4.0× | 1.9×-0.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Citius Oncology, Inc.'s ratios come from?
- Every ratio is computed from Citius Oncology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.